Podcast: Vision Possible – Why Eyestem Is 'Bullish' About Its Dry AMD Candidate

Eyestem founder and CEO talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.

Scrip Podcast Special

Eyestem is advancing its experimental treatment for dry age-related macular degeneration (dry AMD), backed by an underlying vision to develop a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies.

In an interview with Scrip, the Indian cell therapy firm’s founder and CEO, Dr Jogin Desai, said that he’s "very...

More from R&D

More from Scrip